A single contract manager – or even a team of managers – could take weeks or months to manually process and analyze highly complex rebate contracts to gain commercial insights like market trends, drug performance metrics, and customer behavior. Not only is this extremely tedious, this inefficiency compromises revenue optimization, time-to-information, compliance adherence, customer relations and distribution.
Opinion: AI Use In Rebate Management
Pharmaceutical manufacturers face unique challenges, particularly when it comes to managing thousands of complex rebate contracts and connecting the dots between contract agreements and business performance.
More from Market Access
• By
Regenxbio is riding a wave these days, with all three of its clinical-stage programs set to reach critical milestones this year and recent positive news on its DMD gene therapy, just as Sarepta suffered a setback with a death related to its DMD treatment. In Vivo spoke with CEO Curran Simpson about the company’s plans and strategic decisions.
• By
In the pharma and cosmetic sectors, innovation often arises from new uses for known compounds. While the compounds may not be patentable, their new applications can be. European law allows patents on substances used in medical methods, but not on the methods themselves.
• By
In the wake of a series of unprecedented executive orders from US President Trump, the EU medtech industry faces significant political, regulatory and business challenges. Swift and strategic action is essential to ensure stability and safeguard patient safety.
• By
Germany’s Union parties may have little alternative than to bring the SPD into a new four-year coalition, says Clifford Chance partner and life sciences legal expert Gunnar Sachs. Health policy will likely see both textural and structural changes.
More from Business Strategy
• By
In Vivo looks at the top partnerships and investments in AI-driven companies in 2024. Collaborations and investments spanned multiple therapeutic areas, with a particular focus on small molecule discovery, protein degradation and neurological diseases.
• By
The biotech industry faces a surge in litigation due to stricter regulations and patent disputes. This legal storm challenges companies and investors, but there are proactive strategies for mitigating risk in this dynamic landscape.
• By
In September last year, J&J lost a court case surrounding its 2019 purchase of Auris health, and was ordered to pay over $1bn in damages. Reactions to the potentially precedent-setting news were harsh and quick. In Vivo spoke to legal, M&A and BD experts from across the medtech industry to learn more about the true impacts.